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A bs tr ac t
Background
Antibiotics are widely administered to children with the intention of preventing uri-
nary tract infection, but adequately powered, placebo-controlled trials regarding ef-
ficacy are lacking. This study from four Australian centers examined whether low-dose, 
continuous oral antibiotic therapy prevents urinary tract infection in predisposed 
children.
Methods
We randomly assigned children under the age of 18 years who had had one or more 
microbiologically proven urinary tract infections to receive either daily trimethoprim–
sulfamethoxazole suspension (as 2 mg of trimethoprim plus 10 mg of sulfamethox-
azole per kilogram of body weight) or placebo for 12 months. The primary outcome 
was microbiologically confirmed symptomatic urinary tract infection. Intention-to-
treat analyses were performed with the use of time-to-event data.
Results
From December 1998 to March 2007, a total of 576 children (of 780 planned) under-
went randomization. The median age at entry was 14 months; 64% of the patients 
were girls, 42% had known vesicoureteral reflux (at least grade III in 53% of these 
patients), and 71% were enrolled after the first diagnosis of urinary tract infection. 
During the study, urinary tract infection developed in 36 of 288 patients (13%) in the 
group receiving trimethoprim–sulfamethoxazole (antibiotic group) and in 55 of 288 
patients (19%) in the placebo group (hazard ratio in the antibiotic group, 0.61; 95% 
confidence interval, 0.40 to 0.93; P = 0.02 by the log-rank test). In the antibiotic group, 
the reduction in the absolute risk of urinary tract infection (6 percentage points) ap-
peared to be consistent across all subgroups of patients (P≥0.20 for all interactions).
Conclusions
Long-term, low-dose trimethoprim–sulfamethoxazole was associated with a decreased 
number of urinary tract infections in predisposed children. The treatment effect 
appeared to be consistent but modest across subgroups. (Australian New Zealand 
Clinical Trials Registry number, ACTRN12608000470392.)
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Urinary tract infection is a very common illness in children, affecting 2% of boys and 8% of girls by the age of 
7 years.1 Urinary tract infection is associated 
with long-term morbidity, with renal damage re-
ported in about 5% of affected children.2 The 
observation that urinary tract infection and vesi-
coureteral reflux are associated with renal dam-
age3-5 led to the standard clinical practice of as-
sessment with voiding cystourethrography for 
the presence of vesicoureteral reflux in children 
who had had urinary tract infection6,7 and the 
administration of daily low-dose antibiotics for 
many years8 to prevent further urinary tract in-
fections and renal damage in these children. It 
has been recognized that other children without 
reflux are also at risk for recurrent urinary tract 
infection and sequelae, and the use of long-term 
antibiotics has also been recommended for such 
children.9 However, since adequately powered 
and well-designed, placebo-controlled trials of 
long-term antibiotics for the prevention of uri-
nary tract infection in children are lacking,10,11 
current clinical practice has been widely ques-
tioned.12,13 Our study, called the Prevention of 
Recurrent Urinary Tract Infection in Children 
with Vesicoureteric Reflux and Normal Renal 
Tracts (PRIVENT), was designed to determine 
whether the long-term use of low-dose antibiot-
ics prevents recurrent urinary tract infection in 
children.
Me thods
Patients
At four centers in Australia, we recruited children 
from birth to 18 years of age who had had at least 
one symptomatic urinary tract infection.14 Chil-
dren with all grades of vesicoureteral reflux or 
recurrent infection were potentially eligible. Symp-
tomatic urinary tract infection was defined as 
symptoms consistent with such an infection to-
gether with a positive urine culture, which was 
defined as any growth of a pathogenic organism 
from a suprapubic bladder tap or a colony-form-
ing-unit count of 107 or more of a single organ-
ism per liter from a catheter sample or of 108 or 
more of a single organism per liter from a mid-
stream voided urine sample. Children with a 
known neurologic, skeletal, or urologic predis-
posing cause or with a known contraindication 
to trimethoprim–sulfamethoxazole therapy were 
ineligible.
Study Design
Children who had completed short-term treat-
ment, had undergone renal tract imaging (if such 
a study was recommended), and had been clini-
cally asymptomatic before recruitment were ran-
domly assigned to receive either trimethoprim–
sulfamethoxazole (Bactrim, Roche) (antibiotic 
group) or placebo (matched for color, taste, and 
texture) during 12 months of follow-up. The ad-
ministration of the study drug ceased when a 
symptomatic urinary tract infection occurred. 
Trimethoprim–sulfa methoxazole was chosen as 
the study drug because it is consistently recom-
mended as the first-line agent for the prevention 
of urinary tract infection worldwide.6,7,15,16
Investigators, patients, pharmacy staff, out-
come assessors, and the trial biostatistician were 
all unaware of study-group assignments. The ran-
domization sequence was computer-generated and 
stratified according to center, referral source, fre-
quency of previous urinary tract infection, reflux 
status, age, and sex, according to the method of 
minimization.17 Randomization was performed 
centrally by telephone by an independent clinical 
trials center after parents of all patients provided 
written informed consent.
The study was funded by the National Health 
and Medical Research Council of Australia and the 
Financial Markets Foundation for Children of Aus-
tralia. All drugs that were used in the trial were 
purchased. PRIVENT investigators were responsi-
ble for all aspects of the trial.
Urinary Tract Imaging
No requirement for urinary tract imaging was 
mandated for participation in the trial. This pro-
tocol decision reflected the uncertainty surround-
ing the place of renal tract imaging in pediatric 
patients with urinary tract infection worldwide.18 
Using local protocols at each center, we performed 
renal tract ultrasonography, radiologic voiding cys-
tourethrography, and renal scintigraphy with tech-
netium-99m–labeled dimercaptosuccinic acid, with 
89% of studies centrally reviewed. When central 
review was not possible, the routine clinical re-
port was used. Vesicoureteral reflux was graded 
according to the International Reflux Study,19 and 
renal damage was graded according to the crite-
ria of Goldraich et al.20
Study Medication
After consent but before randomization, all chil-
dren received trimethoprim–sulfamethoxazole for 
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2 weeks during a single-blind run-in period. After 
randomization, and at every 3-month visit, the 
study drug was dispensed, with the single daily 
dose calculated by volume according to body weight 
(2 mg of trimethoprim plus 10 mg of sulfamethox-
azole per kilogram of body weight or 0.25 ml of 
suspension [containing 40 mg of trimethoprim and 
200 mg of sulfamethoxazole per 5 ml] per kilo-
gram,9 to the nearest 0.5 ml). Adherence was as-
sessed by comparisons of observed and expected 
volumes remaining in the bottles every 3 months 
and by direct questioning during study visits.
Follow-up Procedures
Children were seen at 3-month intervals during the 
12-month follow-up. At each visit, weight, height, 
and blood pressure were measured, adherence as-
sessed, and primary and secondary outcomes as-
certained with the use of patient diaries and med-
ical records.
Primary and Secondary Outcomes
The primary outcome was symptomatic urinary 
tract infection within 12 months, with the use of 
the same definition as the entry criteria. In the 
event of infection, the study drug was discontinued, 
and routine clinical care was provided for the child 
by the family physician or pediatrician. Children 
were not followed for longer than 12 months.
Secondary outcomes were urinary tract infec-
tion with fever (measured temperature, >38.0°C 
[100.4°F], or a history of fever), hospitalization for 
urinary tract infection, hospitalization for causes 
other than urinary tract infection, antibiotic ad-
ministration for concomitant illness, and deterio-
ration in cortical scintigraphy at 12 months. Scin-
tigraphy was recommended at the completion of 
the study in children who had had an abnormal 
scan at entry or who had a further urinary tract 
infection. During editorial review, urinary tract 
infection from bacteria with resistance to tri-
methoprim–sulfamethoxazole was added as a sec-
ondary outcome.
Statistical Analysis
We aimed to recruit 780 children (390 in each study 
group) on the basis of a clinically important re-
duction in the absolute risk of recurrent symptom-
atic urinary tract infection of approximately 10 per-
centage points between the two groups during 12 
months of follow-up, with an estimated event rate 
of 29% in the placebo group. We determined that 
this number of patients would provide the study 
with a power of 80%, with a two-sided type I error 
of 5% and a nonadherence rate of 10%. An on-
treatment risk of 20% was based on trials of an-
tibiotics in children with and without vesicoureter-
al reflux.10,11 All analyses were performed on the 
basis of the intention-to-treat principle. 
We compared the proportions of children with 
primary and secondary outcomes in the two 
groups using time-to-event analysis for outcomes 
with respect to urinary tract infection and the chi-
square test for other outcomes. The primary out-
come was analyzed with the use of the log-rank 
test. Cox proportional-hazards regression was used 
to obtain unadjusted hazard ratios and to adjust 
for significant stratifying variables and to test for 
effect modification in all secondary analyses. Data 
from children who were lost to follow-up were 
regarded as censored at the time of the last con-
tact. Data from children who did not have a uri-
nary tract infection were censored at 365 days. We 
used Kaplan–Meier estimates of the proportion 
of children with urinary tract infection through-
out. We calculated the number of children who 
would need to be treated to prevent one urinary 
tract infection from the hazard ratio and its 95% 
confidence interval.21
To determine whether the treatment effect 
varied according to the children’s reflux status, 
a priori subgroup analysis was planned with chil-
dren stratified according to the presence and se-
verity of ref lux, and a test of interaction was 
performed in a Cox model. Post hoc subgroup 
analyses were also conducted with the use of other 
stratifying variables, including whether the index 
infection was sensitive or resistant to trimetho-
prim–sulfamethoxazole. Treatment effects were 
described in terms of hazard ratios and absolute 
risk differences with 95% confidence intervals. All 
reported P values are two-sided and have not 
been adjusted for multiple testing.
Figure 1 (facing page). Enrollment and Outcomes.
A total of 13 children (6 in the antibiotic group and 7 in 
the placebo group) did not fulfill eligibility criteria but 
underwent randomization and were subsequently iden-
tified through central data-validation procedures; 29 
children (14 in the antibiotic group and 15 in the place-
bo group) stopped and restarted a study drug. The 
numbers of patients who stopped taking a study drug 
at each time point may not total the number in the final 
analysis because some subsequently restarted a study 
drug. UTI denotes urinary tract infection.
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576 Underwent randomization
9482 Patients were assessed for eligibility
8837 Were excluded
6522 Were ineligible
3811 Did not meet microbiologic criteria
1363 Had predisposing causes
845 Did not meet clinical criteria
503 Had other reasons
2315 Were eligible
1935 Had participation refused by parent
380 Had other reasons
645 Were included in run-in enrollment
69 Were excluded
6 Had sulfa allergy
24 Had difficulties taking antibiotic
10 Had UTI during run-in 
29 Had other reasons
288 Were assigned to receive trimethoprim–
sulfamethoxazole
288 Received intervention (6 were ineligible)
288 Were assigned to receive placebo
288 Received intervention (7 were ineligible)
233 Were taking medication at 3-mo review
55 Had stopped taking medication
13 Had UTI
3 Had adverse drug reaction
39 Had other reasons
212 Were taking medication at 3-mo review
76 Had stopped taking medication
26 Had UTI
10 Had adverse drug reaction
37 Had other reasons
3 Were lost to follow-up
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194 Were taking medication at 9-mo review
15 Had stopped taking medication
8 Had UTI
7 Had other reasons
152 Were taking medication at 9-mo review
26 Had stopped taking medication
11 Had UTI
14 Had other reasons
1 Was lost to follow-up
152 Were taking medication at 12-mo review
(10 restarted)
14 Had stopped taking medication
2 Had UTI
8 Had other reasons
4 Were lost to follow-up
172 Were taking medication at 12-mo review
22 Had stopped taking medication
8 Had UTI
10 Had other reasons
4 Were lost to follow-up
288 Were included in the analysis
136 Had stopped taking medication
55 Had UTI
10 Had adverse drug reaction
63 Had other reasons
8 Were lost to follow-up
288 Were included in the analysis
116 Had stopped taking medication
36 Had UTI
4 Had adverse drug reaction
72 Had other reasons
4 Were lost to follow-up
209 Were taking medication at 6-mo review
24 Had stopped taking medication
7 Had UTI
1 Had adverse drug reaction
16 Had other reasons
178 Were taking medication at 6-mo review
34 Had stopped taking medication
16 Had UTI
18 Had other reasons
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Table 1. Characteristics of the Patients at Baseline.*
Characteristic
Antibiotic Group 
(N = 288)
Placebo Group 
(N = 288)
Age
Median — mo 13.1 14.5
Group — no. (%)
0 to <0.5 yr 61 (21) 53 (18)
0.5 to <1 yr 78 (27) 70 (24)
1 to <2 yr 46 (16) 55 (19)
2 to <4 yr  41 (14) 43 (15)
4 to <10 yr 55 (19) 62 (22)
10 to <15 yr 6 (2) 4 (1)
≥15 yr 1 (<1) 1 (<1)
Female sex — no. (%) 183 (64) 186 (65)
Circumcised — no./total no. (%)
Yes 4/105 (4) 5/102 (5)
No 94/105 (90) 83/102 (81)
Unknown 7/105 (7) 14/102 (14)
History of urinary tract infection — no. (%)†
Index infection only 204 (71) 206 (72)
2 infections 26 (9) 35 (12)
≥3 infections 54 (19) 44 (15)
Index urinary tract infection
With fever‡ 219 (76) 235 (82)
With pyuria§
Yes 191 (66) 197 (68)
No 96 (33) 89 (31)
Unknown 1 (<1) 2 (<1)
Infecting organism — no. (%)
Escherichia coli 251 (87) 252 (88)
Proteus 11 (4) 15 (5)
Klebsiella 9 (3) 11 (4)
Enterococcus 8 (3) 5 (2)
Pseudomonas 4 (1) 1 (<1)
Staphylococcus 2 (1) 0 
Other 3 (1) 4 (1)
Bacterial susceptibility to trimethoprim–sulfamethoxazole  
— no. (%) 
Sensitive 243 (84) 236 (82)
Resistant¶ 42 (15) 44 (15)
Not tested 3 (1) 8 (3)
Maximum grade of vesicoureteral reflux 
None 119 (41) 115 (40)
I or II 57 (20) 57 (20)
III to V 65 (23) 64 (22)
Unknown 47 (16) 52 (18)
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R esult s
Recruitment and Follow-up
From December 1998 through March 2007, we re-
viewed the results of urine testing for 9482 pa-
tients. Of these patients, only 2960 were deemed 
to be eligible to participate in the study. Of the eli-
gible patients, consent was provided for 645 (22%), 
and 576 children (89% of those who provided con-
sent) underwent randomization after the 2-week 
run-in period. Reasons for ineligibility, lack of con-
sent, and exclusion before randomization are pro-
vided in Figure 1.
Enrollment ceased at 576 patients, rather than 
at 780 patients as planned, because of slow re-
cruitment in some centers. The decision to cease 
recruitment was made without any knowledge of 
the outcomes and was based solely on the accrual 
rate. Of the 576 patients who underwent random-
ization, complete follow-up data were obtained for 
564 (98%). A total of 12 children (4 in the anti-
biotic group and 8 in the placebo group) were lost 
to follow-up; 13 children (6 in the antibiotic group 
and 7 in the placebo group) did not fulfill eligi-
bility criteria but underwent randomization and 
were subsequently identified through central da-
ta-validation procedures. Reasons for ineligibility 
were an unconfirmed urinary tract infection (one 
patient), asymptomatic infection (two patients), 
a lack of pure bacterial growth (two patients), 
sample collection from a urine bag (three patients), 
and bacterial growth below threshold (five pa-
tients).
Baseline Characteristics and Adherence
Equal numbers of children (288) were randomly 
assigned to each study group, and baseline char-
acteristics were well matched (Table 1). Overall, the 
median age at entry was 14 months; 64% of the 
patients were girls, 42% had known reflux (at least 
grade III in 53%), and 71% enrolled after the first 
diagnosis of a urinary tract infection. In the two 
Table 1. (Continued.)
Characteristic
Antibiotic Group 
(N = 288)
Placebo Group 
(N = 288)
Results of renal scanning — no. (%)
Abnormal 73 (25) 73 (25)
Normal 160 (56) 162 (56)
Not performed 55 (19) 53 (18)
Study center — no. (%)
Sydney 179 (62) 181 (63)
Canberra 69 (24) 68 (24)
Brisbane 25 (9) 25 (9)
Melbourne 15 (5) 14 (5)
Referral source — no. (%)
Emergency department 163 (57) 158 (55)
General pediatrician 59 (20) 58 (20)
Family physician 35 (12) 40 (14)
Nephrologist 22 (8) 27 (9)
Urologist or other 9 (3) 5 (2)
* Percentages may not total 100 because of rounding.
† Among children who were known to have had at least one previous urinary tract infection, the number of previous in-
fections was not known for four children in the antibiotic group and three in the placebo group. 
‡ The number of children who had urinary tract infection with fever was not known for three children in the antibiotic 
group and four in the placebo group.
§ Pyuria was defined as the presence of at least 100 white cells per cubic millimeter.
¶ Included in this category were nine children (six in the antibiotic group and three in the placebo group) whose index in-
fection was caused by enterococcus or pseudomonas. These bacteria were not tested for susceptibility to trimethoprim–
sulfamethoxazole but were assumed to be resistant. Also included were 20 children (12 in the antibiotic group and 8 in 
the placebo group) whose index infection was caused by bacteria that were resistant to trimethoprim but that were not 
tested for resistance to sulfamethoxazole.
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groups, approximately 87% of the index infections 
were caused by Escherichia coli, and 15% of the in-
fecting bacteria were resistant to trimethoprim–
sulfamethoxazole.
During the study period, a number of patients 
stopped taking a study drug for reasons other than 
the diagnosis of symptomatic urinary tract infec-
tion: 90 of 576 patients (16%) at 3 months, 122 of 
514 patients (24%) at 6 months, 141 of 495 patients 
(28%) at 9 months, and 151 of 485 patients (31%) 
at 12 months. A total of 29 children (15 in the 
antibiotic group and 14 in the placebo group) 
stopped and restarted a study drug during the 
12-month period. Fourteen children (4 in the an-
tibiotic group and 10 in the placebo group) (2%) 
permanently discontinued a study drug because 
of a mild adverse drug reaction. There was no dif-
ference in the frequency of reported nonadherence 
between the antibiotic group and the placebo 
group.
Primary Outcome
During the study period, urinary tract infection was 
diagnosed in 36 of 288 patients (13%) in the an-
tibiotic group and in 55 of 288 (19%) in the pla-
cebo group (hazard ratio in the antibiotic group, 
0.61; 95% confidence interval [CI], 0.40 to 0.93; 
P = 0.02 by the log-rank test), a difference of 6 per-
centage points (95% CI, 1 to 13) (Fig. 2). Thus, at 
12 months, 14 patients (95% CI, 9 to 86) would 
need to have been treated to prevent one urinary 
tract infection. Half the events in the placebo group 
occurred within 3 months after randomization; an 
additional 25% occurred during the next 3 months. 
The spectrum of infecting bacteria was similar in 
the two groups, with Escherichia coli identified as 
the causative bacterium in 30 of 36 patients (83%) 
in the antibiotic group and in 46 of 55 patients 
(84%) in the placebo group.
The effect of trimethoprim–sulfamethoxazole 
on the prevention of symptomatic urinary tract 
infection did not vary significantly according to 
any stratifying variable: age, sex, reflux status, his-
tory of more than one urinary tract infection, or 
susceptibility of the causative organism for the 
index infection to trimethoprim–sulfamethoxazole. 
The relative hazard did not vary significantly, and 
the absolute risk difference was 6 to 8 percentage 
points across all subgroups (Fig. 3, and Table 1 
in the Supplementary Appendix, available with the 
full text of this article at NEJM.org). The point 
estimates favored trimethoprim–sulfamethoxazole 
for all subgroups except for the group of children 
who had an index urinary tract infection caused 
by an organism that was resistant to trimetho-
prim–sulfamethoxazole.
Secondary Outcomes
The frequency of secondary outcomes was numer-
ically lower, but generally not significantly lower, 
in the antibiotic group than in the placebo group, 
with the exception of urinary tract infection from 
bacteria that were resistant to trimethoprim–sul-
famethoxazole, which occurred more frequently in 
the antibiotic group (Table 2). During the study 
period, urinary tract infection with fever developed 
in 19 of 288 patients (7%) in the antibiotic group 
and in 36 of 288 patients (13%) in the placebo 
group (hazard ratio, 0.49; 95% CI, 0.28 to 0.86; 
P = 0.01), a difference of 6 percentage points (95% 
CI, 1 to 11) (Fig. 4). The effect of trimethoprim–
sulfamethoxazole on the prevention of symptom-
atic febrile urinary tract infection did not vary 
significantly according to any stratifying variable 
in either relative or absolute terms (Fig. 3, and 
Table 2 in the Supplementary Appendix).
The progression of abnormal results on renal 
scanning from baseline to follow-up did not differ 
significantly between the antibiotic group and the 
placebo group, although, as expected, very few 
patients had a worsening of scanning results at 
12 months, as compared with baseline. Fewer hos-
pitalizations and adverse drug reactions occurred 
in the antibiotic group than in the placebo group, 
but the differences were not significant. Although 
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Figure 2. Time to Symptomatic Urinary Tract Infection (UTI) (Primary Outcome).
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the number of children who received at least one 
course of antibiotics for a cause other than urinary 
tract infection was not significantly lower in the 
antibiotic group, a test for trend showed that chil-
dren in the placebo group were more likely to re-
ceive more courses of antibiotics than were chil-
dren in the antibiotic group (Table 2).
Discussion
Long-term, low-dose trimethoprim–sulfamethox-
azole was associated with a modest decrease in 
the number of symptomatic urinary tract infections 
in predisposed children, with a reduction in ab-
solute risk of 6 percentage points. This finding 
means that 14 children would need to be treated 
to prevent one case of urinary tract infection. The 
absolute treatment effect appeared to be consis-
tent across a wide range of risk factors for fur-
ther urinary tract infection. The pattern of recur-
rence suggested that the benefit of antibiotic 
therapy was greatest during the first 6 months of 
treatment, the most likely time for recurrent in-
fection. Although trimethoprim–sulfamethoxazole 
prevented urinary tract infection overall, our data 
suggest that prolonged administration resulted 
in changes in the susceptibility of pathogenic bac-
teria, with an increased risk of symptomatic uri-
nary tract infection caused by bacteria that were 
resistant to trimethoprim–sulfamethoxazole. The 
results indicated that children with an index in-
fection that was resistant to trimethoprim–sul-
famethoxazole might not benefit from such pro-
phylaxis.
Any benefits of long-term antibiotic use in re-
ducing the risk of new kidney damage from pyelo-
nephritis remain speculative, since our study was 
not powered to analyze this outcome. However, 
given the modest reduction in the risk of urinary 
tract infection in the antibiotic group and the low 
risk of new damage (5%) occurring with a single 
infection,2 the magnitude of the benefits is likely 
to be small at best. Our findings are strength-
ened by the finding that there was a reduced risk 
of febrile urinary tract infection among children 
in the antibiotic group. Concern that the long-term 
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Figure 3. Effect of Trimethoprim–Sulfamethoxazole on the Risk of Symptomatic Urinary Tract Infection (UTI)  
with and without Fever.
The differences in risk rather than hazard ratios are shown for subgroups of patients receiving either trimethoprim–
sulfamethoxazole (antibiotic group) or placebo because the risk difference appeared to be a more consistent measure 
and more clinically applicable. No significant interactions were identified among the various subgroups of patients. 
The horizontal bars represent 95% confidence intervals. 
The New England Journal of Medicine 
Downloaded from nejm.org on September 8, 2013. For personal use only. No other uses without permission. 
 Copyright © 2009 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 361;18 nejm.org october 29, 20091756
use of antibiotics in such patients may predispose 
to infections other than urinary tract infection 
was probably unfounded, since the rate of such 
infections that were severe enough to warrant the 
use of antibiotics was lower in the antibiotic group 
than in the placebo group.
Data from randomized, controlled trials to in-
form the treatment of children with urinary tract 
infection have been sparse.22 In the 1970s, four 
trials of the prophylactic use of antibiotics tended 
to favor the antibiotic group.23-26 However, the 
combined studies involved only 171 children, of 
Table 2. Secondary Outcomes.
Outcome
Antibiotic Group 
(N = 288)
Placebo Group 
(N = 288)
Risk Difference 
(95% CI)* P Value
no. (%)
Urinary tract infection with fever† 19 (7) 36 (13) 6 (1 to 11) 0.01
Hospitalization for urinary tract infection 23 (8) 29 (10) 2 (−3 to 7) 0.38
Urinary tract infection with organism resistant to 
trimethoprim–sulfamethoxazole‡
24 (67) 13 (25) −42 (−61 to −22) <0.001
Adverse drug reaction 4 (1) 10 (3) 2 (0 to 5) 0.10
Use of antibiotic for other infectious disease
Any episode 123 (43) 141 (49) 6 (−2 to 14) 0.13
No. of episodes 
0 165 (57) 147 (51) 0.04§
1 66 (23) 65 (23)
2 37 (13) 42 (15)
3 12 (4) 18 (6)
4 3 (1) 11 (4)
≥5 5 (2) 5 (2)
Renal scan at 1 yr¶
No. of patients 71 83
Normal results 36 (51) 45 (54) 4 (−12 to 19) 0.87
Unchanged as compared with baseline 12 (17) 28 (34)
Resolved as compared with baseline 19 (27) 15 (18)
No baseline scan 5 (7) 2 (2)
Abnormal results 35 (49) 38 (46)
Improved as compared with baseline 9 (13) 12 (14)
Unchanged as compared with baseline 18 (25) 19 (23)
Worse as compared with baseline 5 (7) 7 (8)
No baseline scan 3 (4) 0
* Positive numbers indicate higher risk in the placebo group, and negative numbers increased risk in the antibiotic group. Values may not 
equal the numerical between-group differences because of rounding. 
† The number of children who had a urinary tract infection with fever was not known for five children in each group. For this outcome, P val-
ues were calculated with the use of the log-rank test, and percentages are Kaplan–Meier estimates.
‡ The percentages in this category are the proportions of patients with resistant bacteria in whom urinary tract infection was diagnosed and 
for whom the susceptibility to either trimethoprim or trimethoprim–sulfamethoxazole was known (36 in the antibiotic group and 52 in the 
placebo group). Two children (one in the antibiotic group and one in the placebo group) had one or more subsequent urinary tract infec-
tions that were caused by enterococcus or pseudomonas; these organisms were not tested for susceptibility to trimethoprim–sulfamethox-
azole but were assumed to be resistant. Eight children (six in the antibiotic group and two in the placebo group) had infections caused by 
bacteria that were resistant to trimethoprim but that were not tested for resistance to sulfamethoxazole. Resistance was not tested in three 
children in the placebo group. The P value for this comparison was calculated with the chi-square test.
§ The P value was calculated with the use of the Mantel–Haenszel test for trend.
¶ The percentages in this category are the proportions of patients with various results who underwent renal scanning at 1 year. Results of re-
nal scanning at 1 year were not known for 22 children in the antibiotic group and 17 in the placebo group who had abnormal results at 
baseline. The P value for this comparison was calculated with the chi-square test of proportions with a normal scan at 1 year.
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whom only 32 had reflux, and methodologic limi-
tations and the reporting of positive urine cultures 
rather than clinically important, symptomatic uri-
nary tract infection limited the applicability of 
those trials.
Despite such weak evidence, a 20-year hiatus 
in trials followed, during which time antibiotic 
prophylaxis was considered to be good clinical 
practice, making the use of placebo in a trial un-
ethical. During the past decade, as a reflection of 
the growing uncertainty regarding the efficacy of 
antibiotic prophylaxis for urinary tract infection, 
the results of five randomized, controlled trials 
of antibiotics in children with and without reflux 
have been published.27-31 However, none of these 
trials were placebo-controlled or reported adher-
ence. Furthermore, all the trials were underpow-
ered, with sample sizes of between 100 and 218 
patients.10,11,32 These trials did not show a ben-
efit for prophylactic antibiotics, with the abso-
lute difference in the risk of symptomatic urinary 
tract infection in the antibiotic group ranging from 
a reduction of 0.9 percentage points to an increase 
of 6.0 percentage points. The discordance of these 
results with our findings may be explained by the 
lack of adherence to long-term antibiotic use, a 
lack of statistical power, and unbalanced co-
interventions in the earlier trials. We await with 
interest the results of the ongoing, placebo-
controlled Randomized Intervention for Chil-
dren with Vesicoureteral Reflux (RIVUR) study 
(ClinicalTrials.gov number, NCT00405704),33 
which is being funded by the National Insti-
tutes of Health. A recent data-linkage cohort 
study34 showed no benefit for antibiotic prophy-
laxis, but the observational nature of the study 
creates the potential for residual selection bias, 
and reliance on linked data for outcomes ascer-
tainment renders the validity of these findings 
uncertain.
Our study had potential limitations. We planned 
to recruit 780 children but recruited only 576, 
largely because of a changing attitude away from 
using prophylactic antibiotics during the nearly 
10-year recruitment period. However, our study 
was adequately powered to show a reduction in 
the rate of symptomatic urinary tract infection, 
and these analyses are valid because the study was 
terminated without regard for outcomes. Our 
study was not designed to estimate the effect of 
trimethoprim–sulfamethoxazole on the progres-
sion of renal damage, as seen on renal scans. 
Given the very low rate of persistent kidney dam-
age after a single urinary tract infection and the 
modest benefit of antibiotics, a trial would need 
to enroll at least two to three times the number 
of patients in our study to show benefit in such 
patients. Only 4% of boys in the study were cir-
cumcised, which reflects the current rate of cir-
cumcision among boys in Australia. Accordingly, 
the study was not designed to address the incre-
mental effect of trimethoprim–sulfamethoxazole 
over circumcision.35
Since the rate of adverse events did not differ 
between the two study groups and the risk of in-
fections other than urinary tract infection that 
were severe enough to require the use of antibi-
otics was lower in the antibiotic group, it would 
be reasonable for clinicians to recommend the 
use of trimethoprim–sulfamethoxazole in chil-
dren who are at high risk for infection or whose 
index infection was severe. Established risk fac-
tors for urinary tract infection are female sex, 
vesicoureteral reflux, and, particularly, recurrent 
urinary tract infection.34,36 In children who have 
had a single symptomatic urinary tract infection, 
prophylaxis with trimethoprim–sulfamethoxazole 
should be considered but not routinely recom-
mended. The modest size of the benefit and the 
possibility of rare but serious complications from 
the use of trimethoprim–sulfamethoxazole, such 
as the Stevens–Johnson syndrome,37 suggest that 
the drug should not be used prophylactically in 
children who have never had a symptomatic uri-
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Figure 4. Time to Urinary Tract Infection (UTI) with Fever (Secondary  
Outcome).
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nary tract infection (e.g., those with congenital 
hydronephrosis or siblings with reflux).
In conclusion, our results indicate that long-
term, low-dose antibiotic use was associated with 
a modest reduction (7 percentage points) in the 
absolute risk of symptomatic urinary tract infec-
tion in predisposed children, regardless of age, 
sex, frequency of previous urinary tract infection, 
and concomitant reflux, and may reduce the like-
lihood that antibiotics will be required for other 
infections.
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